DBV Technologies

DBV Technologies is one of the...

• CAC All-Trade.

DBV Technologies is a company listed under the stock ticker DBV (FR).

View the org chart displaying its 17 main executives

Most searched biographies at DBV Technologies

• Daniel Tasse, Chief Executive Officer and Director
• Julie O'Neill, Director
• Maïlys Ferrere, Director

Popular executive movements at DBV Technologies

• Sebastien Robitaille, Chief Financial Officer, will leave the company on Nov. 17, 2023  (posted on October 16 2023).
• Virginie Boucinha will join the company as Chief Financial Officer on Nov. 6, 2023  (posted on October 16 2023).

Create your alert
to follow the executive moves at DBV Technologies.

DBV Technologies has 1,869 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by DBV Technologies

• Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 | DBV Technologies
• DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 | DBV Technologies
• DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document | DBV Technologies
• DBV Technologies Reports Full Year 2023 Financial Results and Business Update | DBV Technologies
• News | DBV Technologies
• DBV Technologies to Participate in Upcoming AAAAI 2024 Congress | DBV Technologies
• Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023   | DBV Technologies
• DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers | DBV Technologies
• Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 | DBV Technologies
• DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results | DBV Technologies
• View more press releases Close

Social media about DBV Technologies

• DBV Technologies on Wikipedia, Google News & Yahoo Finance
• DBV Technologies on LinkedIn, Twitter & YouTube

Contact by email its executives including Daniel Tasse

Call DBV Technologies at +33 15...

View the org chart

Register to receive your alert

Report an error